Commentary on Pharmacometrics for Immunotherapy

This commentary provides an overview of recent examples of pharmacometrics applied during the clinical development of two antagonists of the programmed death‐1 (PD‐1) cell surface receptor, pembrolizumab and nivolumab. Despite the remarkable achievements obtained in predicting the correct dosing sch...

Descripción completa

Detalles Bibliográficos
Autores principales: Garrido, MJ, Berraondo, P, Trocóniz, IF
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270298/
https://www.ncbi.nlm.nih.gov/pubmed/27997736
http://dx.doi.org/10.1002/psp4.12162
_version_ 1782501163105517568
author Garrido, MJ
Berraondo, P
Trocóniz, IF
author_facet Garrido, MJ
Berraondo, P
Trocóniz, IF
author_sort Garrido, MJ
collection PubMed
description This commentary provides an overview of recent examples of pharmacometrics applied during the clinical development of two antagonists of the programmed death‐1 (PD‐1) cell surface receptor, pembrolizumab and nivolumab. Despite the remarkable achievements obtained in predicting the correct dosing schedule from different quantitative approaches, data indicated a great degree of heterogeneity in tumor response. To achieve therapeutic goals the search for predictive biomarkers associated with a lack of response and mechanism‐based combination studies are warranted.
format Online
Article
Text
id pubmed-5270298
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-52702982017-02-01 Commentary on Pharmacometrics for Immunotherapy Garrido, MJ Berraondo, P Trocóniz, IF CPT Pharmacometrics Syst Pharmacol Commentary This commentary provides an overview of recent examples of pharmacometrics applied during the clinical development of two antagonists of the programmed death‐1 (PD‐1) cell surface receptor, pembrolizumab and nivolumab. Despite the remarkable achievements obtained in predicting the correct dosing schedule from different quantitative approaches, data indicated a great degree of heterogeneity in tumor response. To achieve therapeutic goals the search for predictive biomarkers associated with a lack of response and mechanism‐based combination studies are warranted. John Wiley and Sons Inc. 2017-01-17 2017-01 /pmc/articles/PMC5270298/ /pubmed/27997736 http://dx.doi.org/10.1002/psp4.12162 Text en © 2016 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Commentary
Garrido, MJ
Berraondo, P
Trocóniz, IF
Commentary on Pharmacometrics for Immunotherapy
title Commentary on Pharmacometrics for Immunotherapy
title_full Commentary on Pharmacometrics for Immunotherapy
title_fullStr Commentary on Pharmacometrics for Immunotherapy
title_full_unstemmed Commentary on Pharmacometrics for Immunotherapy
title_short Commentary on Pharmacometrics for Immunotherapy
title_sort commentary on pharmacometrics for immunotherapy
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270298/
https://www.ncbi.nlm.nih.gov/pubmed/27997736
http://dx.doi.org/10.1002/psp4.12162
work_keys_str_mv AT garridomj commentaryonpharmacometricsforimmunotherapy
AT berraondop commentaryonpharmacometricsforimmunotherapy
AT troconizif commentaryonpharmacometricsforimmunotherapy

Ejemplares similares